Literature DB >> 26051170

Endovascular treatment of wide-neck anterior communicating artery aneurysms using the LVIS Junior stent.

Zhengzhe Feng1, Lei Zhang2, Qiang Li1, Rui Zhao1, Yi Xu1, Bo Hong1, Wenyuan Zhao1, Jianmin Liu1, Qinghai Huang3.   

Abstract

We performed this retrospective study to assess the clinical safety and efficacy of the low-profile visualized intraluminal support junior (LVIS Jr.; MicroVention, Aliso Viejo, CA, USA) stent placement in anterior communicating artery (ACA) aneurysms. ACA aneurysms are some of the most common intracranial aneurysms. Stent placement is particularly difficult due to the complexity of the vascular anatomy and the small vessels of the ACA complex. From November 2013 and June 2014, LVIS Jr. stent-assisted coiling was performed in 11 patients with 12 wide-neck ACA aneurysms. Patient demographics, morphologic features of the aneurysm, clinical results and follow-up results are presented. Successful deployment of the LVIS Jr. stent in the targeted artery was achieved in all patients. Complete occlusion was achieved in seven patients, neck remnant in three, and partial occlusion in two. The angiographic follow-up of nine patients (mean 4.4 months) showed that all aneurysms remained stable or improved. There was no in-stent stenosis, recurrence or retreatment. The modified Rankin scale score at discharge was 0 in eight patients and 1 in three patients. The LVIS Jr. stent provided excellent trackability and deliverability and is safe and effective for the treatment of wide-necked ACA aneurysms. Further follow-up is needed to assess the long-term efficacy of LVIS Jr. stent placement in ACA.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aneurysm; Anterior communicating artery; Stent; Wide-neck

Mesh:

Substances:

Year:  2015        PMID: 26051170     DOI: 10.1016/j.jocn.2015.02.020

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  6 in total

1.  LVIS Jr. stent for treatment of intracranial aneurysms with parent vessel diameter of 2.5 mm or less.

Authors:  Alejandro Santillan; Srikanth Boddu; Justin Schwarz; Ning Lin; Y Pierre Gobin; Jared Knopman; Athos Patsalides
Journal:  Interv Neuroradiol       Date:  2018-02-20       Impact factor: 1.610

2.  Safety and Efficacy of Low-Profile, Self-Expandable Stents for Treatment of Intracranial Aneurysms: Initial and Midterm Results - A Systematic Review and Meta-Analysis.

Authors:  Su-Yeon Park; Jae-Sang Oh; Hyuk-Jin Oh; Seok-Mann Yoon; Hack-Gun Bae
Journal:  Interv Neurol       Date:  2017-04-26

3.  Endovascular treatment of patients with intracranial aneurysms: feasibility and successful employment of a new low profile visible intraluminal support (LVIS) EVO stent.

Authors:  Alexander Sirakov; Pervinder Bhogal; Markus Möhlenbruch; Stanimir Sirakov
Journal:  Neuroradiol J       Date:  2020-07-21

4.  Low-profile Visualized Intraluminal Support Junior Device for the Treatment of Intracranial Aneurysms.

Authors:  Mihir Gupta; Vincent J Cheung; Peter Abraham; Arvin R Wali; David R Santiago-Dieppa; Brandon C Gabel; Abdulrahman Almansouri; J Scott Pannell; Alexander A Khalessi
Journal:  Cureus       Date:  2017-02-17

5.  Safety and effectiveness of the Low Profile Visualized Intraluminal Support (LVIS and LVIS Jr) devices in the endovascular treatment of intracranial aneurysms: results of the TRAIL multicenter observational study.

Authors:  Christina Iosif; Michel Piotin; Suzana Saleme; Xavier Barreau; Jacques Sedat; Yves Chau; Nader Sourour; Mohamed Aggour; Herve Brunel; Alain Bonafe; Paolo Machi; Carlos Riquelme; Vincent Costalat; Laurent Pierot; Raphael Blanc; Charbel Mounayer
Journal:  J Neurointerv Surg       Date:  2017-11-24       Impact factor: 5.836

Review 6.  Anterior Communicating Artery Aneurysms: Anatomical Considerations and Microsurgical Strategies.

Authors:  Junhui Chen; Mingchang Li; Xun Zhu; Yan Chen; Chunlei Zhang; Wenwen Shi; Qianxue Chen; Yuhai Wang
Journal:  Front Neurol       Date:  2020-09-08       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.